Literature DB >> 19816206

Enlarged and prominent nucleus may be indicative of tetraploidy: a laboratory study of a rare near-tetraploidy in a child patient with acute myelogenous leukemia AML-M4.

Ji-Hong Zhang1, Ying-Chun Zheng, Yun-Xiu Wang, Jun-Yan Zhang, Zhuo-Gang Liu.   

Abstract

SUMMARY: Near-tetraploidy is a rare cytogenetic abnormality in myelocytic malignancies in children and its significance is unknown. To investigate the pathologic characteristics of a near-tetraploidy in a child with acute myelogenous leukemia (AML-M4), bone marrow smears were prepared for morphologic analysis. Bone marrow samples were collected at presentation for flow cytometry, prepared by short-term (24 h) unstimulated culture and R-banding for conventional cytogenetic assay. We have performed a multifactorial analysis of the laboratory test results. In this case, the chromosomal analysis (R-banding) demonstrated a near-tetraploidy. Combined with morphologic and immunophenotypic results, the diagnosis was established as acute myelogenous leukemia (AML-M4). Near-tetraploidy is an uncommon cytogenetic finding, and the experience of this case further emphasizes the importance of the laboratory diagnostic methods.

Entities:  

Mesh:

Year:  2010        PMID: 19816206     DOI: 10.1097/MPH.0b013e3181b794b2

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  3 in total

1.  Clinicopathological analysis of near-tetraploidy/tetraploidy acute myeloid leukaemia.

Authors:  Changlee S Pang; Mark J Pettenati; Timothy S Pardee
Journal:  J Clin Pathol       Date:  2015-01-06       Impact factor: 3.411

2.  Two cases of near-tetraploidy in acute leukemias of ambiguous lineage.

Authors:  Bo Hyun Kim; Hye Ryoun Kim; Mi-Kyung Lee; Hyunyoung Chi
Journal:  Ann Lab Med       Date:  2013-08-08       Impact factor: 3.464

3.  Telomere Shortening in Hematological Malignancies with Tetraploidization-A Mechanism for Chromosomal Instability?

Authors:  Eigil Kjeldsen
Journal:  Cancers (Basel)       Date:  2017-11-30       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.